Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock
December 15, 2020 16:01 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
December 14, 2020 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
November 30, 2020 16:05 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
November 27, 2020 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals to Host Virtual Investor Day
November 19, 2020 16:05 ET
|
Phathom Pharmaceuticals
Event to be webcast on Monday, December 14, 2020 at 1:00 PM (ET) FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage...
Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
November 13, 2020 16:05 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials
November 10, 2020 16:05 ET
|
Phathom Pharmaceuticals
Pivotal Phase 3 PHALCON-EE trial enrollment expected to complete before year-end 2020; top-line results expected in the second half of 2021Pivotal Phase 3 PHALCON-HP trial enrollment expected to...
Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference
September 09, 2020 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports Second Quarter 2020 Results
August 06, 2020 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
July 13, 2020 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...